Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

GPCR Desensitization01:12

GPCR Desensitization

6.2K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Discovery and biological evaluation of HS13 as a novel covalent ligand targeting the NSD2-PWWP1 domain.

Bioorganic & medicinal chemistry·2026
Same author

Identification of novel covalent ligands that disrupt Acetyl-Lysine binding to the SETDB1 tudor domain.

Biochemical and biophysical research communications·2026
Same author

Structure-based design of the approved drug zafirlukast identifies HLC40 as a potent WDR5 WIN-site inhibitor with antitumor efficacy.

Bioorganic chemistry·2026
Same author

Structural basis for sequence-specific DNA recognition by a group IId WRKY transcription factor GhWRKY17 in cotton.

The Biochemical journal·2026
Same author

Biochemical and structural studies of NFIA and NFIC reveal a conserved mechanism for specific DNA recognition and provide insight into potential pathogenicity of disease-associated mutations.

Acta biochimica et biophysica Sinica·2025
Same author

Fragment-Based Screening of NSD2-PWWP1 Identifies Novel Covalent Allosteric Ligands That Diminish Methyllysine and DNA Binding Abilities of NSD2.

Journal of medicinal chemistry·2025

相关实验视频

Updated: Jul 28, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

对于 PROTAC 应用的 N/C 降解途径和抑制剂的发展.

Zhibin Wu1, Yunyuan Huang1, Ke Liu1

  • 1Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan 430079, PR China.

Biochimica et biophysica acta. Gene regulatory mechanisms
|June 1, 2023
PubMed
概括

本综述详细介绍了E3泛素连接酶和泛素化机制,重点关注N/C降解通路. 它还探讨了针对治疗应用的向抑制剂和PROteolysis TTargeting Chimeras (PROTACs).

关键词:
这是 Degron Degron 的意思.E3 无处不在的合酶针对蛋白质溶解的喜梅拉 (PROTAC)在Ubiquitination中使用.

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.8K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.5K

相关实验视频

Last Updated: Jul 28, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.8K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.5K

科学领域:

  • 生物化学 生物化学
  • 分子生物学分子生物学
  • 细胞生物学 细胞生物学

背景情况:

  • 乌比基因化是一种关键的翻译后修饰,它调节了许多细胞过程.
  • 在确定基质特异性方面,E3无素连接酶发挥着中心作用.
  • 了解无处不在的途径对于破译细胞功能和疾病机制至关重要.

研究的目的:

  • 为了提供对E3泛素连接酶和泛化进行全面的概述.
  • 检查N/C-degron介导的泛素化途径及其机制.
  • 讨论针对这些途径的治疗潜力,包括抑制剂和PROTACs.

主要方法:

  • 关于无处不在的途径的文献综述.
  • 分析E3无素结合酶的分类和功能.
  • 检查N / C降解机制和基质识别.
  • 对N/C降解抑制剂和PROTACs当前发展的审查.

主要成果:

  • 详细的分类和机制的洞察力E3无素连接酶.
  • 阐明N/C降解通路的独特特征和基质识别.
  • 针对无处不在的新兴治疗策略的概述.

结论:

  • 乌比奎丁生物学是一个快速发展的领域,具有重要的治疗意义.
  • 针对N/C-degron途径为药物开发提供了有前途的途径.
  • 蛋白质溶解向基因组 (PROTACs) 是一种新的治疗方式,用于基因介导的蛋白质降解.